3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Gemcitabine
358
Fluorouracil
94
Oxaliplatin
81
Capecitabine
74
130-nm albumin-bound paclitaxel
71
Albumin-Bound Paclitaxel
70
Radiotherapy
67
Leucovorin
58
Irinotecan
49
Erlotinib Hydrochloride
47
Cisplatin
44
Bevacizumab
31
pembrolizumab
30
Radiosurgery
30
Docetaxel
26
Taxes
24
Nivolumab
24
Cetuximab
24
Pancreaticoduodenectomy
20
Drug Therapy
17
folfirinox
16
Cyclophosphamide
16
Radiation
15
Ipilimumab
13
Endoscopic Ultrasound-Guided Fine Needle Aspiration
13
Surgical Procedures, Operative
12
Sorafenib
12
Paclitaxel
12
Neoadjuvant Therapy
12
irinotecan sucrosofate
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Pancreatic Neoplasms
×
rocakinogene sifuplasmid
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled